

Objectives

- Discuss the perimenopause transition
- Identify symptoms related to perimenopause
- Review treatment options for common symptoms of perimenopause
- 2

Definition - "around menopause"

- The time when a woman's body begins transitioning to menopause
- Ovaries gradually stop ovulating
- Begins with the first onset of menstrual irregularity and ends after one year of amenorrhea has occurred

3

STRAW stages of reproductive aging surrounding menopause transition

- Late Reproductive
- Cycles regular to slightly irregular
- Normal to variable FSH
- Ovarian reserve low
- Early Perimenopause
- Cycles and FSH variable
- Ovarian reserve low
- Cycles > 60 days apart
 FSH high
 Ovarian reserve low

Late Perimenopause

- Menopause
- Menses have ended
- FSH high

Ovarian reserve undetectable

Definition

- Average age at start 40-44
- Marked by changes in menstrual flow and length of cycle
- Loss of ovarian reserve during perimenopause
- Menopause = follicle failure —> granulosa cells no longer respond to FSH signal resulting in loss of estradiol production

4

Early Perimenopause

- Follicle cohort is relatively preserved, rises in FSH cause folliculogenesis to occur more rapidly
- Increase in luteal phase follicle growth (eg next cycle's dominant follicle has already started to grow)
- Ovulations follow rapidly upon one another
- Short follicular phase, relatively longer luteal phase so increased PMS symptoms
- Lower luteal progesterone, higher FSH
- Erratic estrogen secretion

5

Late Perimenopause

- Menses highly irregular, menstrual periods are scarce
- Estradiol low
- Loss of negative feedback from estradiol results in increased FSH and LH
- Long periods of amenorrhea
- When there is a menstrual cycle it may be ovulatory, anovulatory with high estrogen levels, or anovulatory with low estrogen levels

7

Perimenopausal AUB = diagnosis of exclusion

- Endometrial tissue sampling should be performed in patients with AUB who are older than 45 years as a first line test
- Endometrial tissue sampling should also be performed in patients younger than 45 years with h /o unopposed estrogen exposure (obesity /pcos), failed medical mgmt, and persistent AUB

8

Perimenopausal AUB treatment

- Hormonal contraception
- OCP
- · Levonorgestrel IUD
- Endometrial ablation
 - Should only be done if sterilization has and will concomitantly occur
- Hysterectomy
- Tranexamic acid

9

Hot Flashes

- Reported in 30-70% of pre menopausal women
- Increase in prevalence during early perimenopause to up to 85%
- Highest incidence in African-American and Native American populations
- Lowest incidence in Chinese and Japanese women

Perimenopaual Symptoms

- Hot flushes
- Depressed moodIncreased anxiety
- Poor sleep
 - Vaginal dryness /dyspareuni
 - Other brain fog, generalized joint pain

10

a

Hot Flashes

- High BMI: worse hot flashes during perimenopause, fewer milder hot flashes in menopause
- Elevated FSH is predictive of hot flashes (not necessarily estradiol level)
- Higher incidence in patients with anxiety, depression, and in smokers

Hot Flashes

- Duration up to 10 years is common
 - * 20% women in their 50s
 - 10% women in their 60s
 - * 5% women in their 70s

13

Hot Flashes - Health implications

- Decreased quality of life
- Increased cardiovascular disease risk
- Increased risk dementia

14

Sleep Changes

- Changes in sleep patterns start age 40s and worsen through perimenopause - incidence up to 40%
- Many postmenopausal patients report insomnia
- Due in part to hot flashes but likely multifactorial

15

Depressed Mood/Anxiety

- Depression and anxiety symptoms more likely to be reported by women who are perimenopausal
- In SWAN study, baseline depression symptoms 20.9%, 27.8% in early perimenopause, 25.2% late perimenopause, 22% postmenopause
- Major depression more common during the late perimenopause stage
- SWAN study Major Depression OR 2.27 in perimenopause, 3.57 in post-menopause
- Anxiety scores seemed to worsen as perimenopause progresses

Vaginal Dryness

- Up to 33% of women during perimenopause
- Does not improve without treatment

16

Treatment: vasomotor symptoms (VMS)

- Hormone therapy most effective at improving quality of life
 - Contraindications: ER+ cancer; h/o stroke, mi or VTE; thrombophilia, severe active liver disease
 - May slow progression of CVD when used during ages 45-55
- Menopausal hormone therapy dose about 1/4 equivalent estrogen dose as oral contraceptive pill
- * If breakthrough bleeding OCP indicated
 - Best to use continuous OCP rather than placebo week to avoid symptoms

Treatment: VMS

- Remember to use progestin in patients using estrogen therapy with a uterus to avoid endometrial cancer
- Concurrent use of estrogen and continuous levonorgestrel intrauterine system
- Non-oral estrogen is preferred due to decreased risk for VTE

19

Treatment: VMS

- Some SSRIs and SNRIs have been shown to reduce VMS by up to 69%
- Paroxetine salt 7.5 mg (long acting): FDA approved for vasomotor symptoms
- SSRI: citalopram, escitalopram
 - No significant improvement in VMS with sertraline or fluoxetine
- SNRI: desvenlafaxine, venlafaxine

20

Treatment: VMS

- Gabapentin
 - improves the frequency and severity of VMS
 - Start with 100-300 mg at night, titrate to goal 900 mg/day; max dose 2400 mg/day
 - AE: drowsiness, dizziness, impaired balance/coordination
 - · Of note, pregabalin is not recommended for VMS

21

Treatment: VMS

Clonidine

- Has been shown to be modestly more effective than placebo
- AE: hypotension, lightheadedness, headache, dry mouth, dizziness, sedation, constipation; sudden cessation can cause acute hypertension
- Not recommended because there are more effective therapies with fewer AE's

22

Treatment: VMS

- Oxybutynin
 - Doses range 2.5 mg or 5 mg bid up to 15 mg XR daily
 - Several studies show significant improvement for moderate to severe VMS
 - AE: dry mouth, urinary difficulty, cognitive decline (with prolonged use)

Treatment: VMS

- Fezolinetant (Veozah)
 - FDA approved NONHORMONAL treatment for VMS in POSTmenopause
 - Neurokinin B antagonist
 - With loss of estrogen suppression, there is hyperactivity of the KNDy neurons, resulting in hypersecretion of neurokinin B
 - NKB then stimulates the adjacent thermoregulatory center in the hypothalamus to cause VMS

Treatment: VMS

- Cognitive behavioral therapy CBT
 - Has been shown to clinically reduce the degree to which VMS are rated as a problem (eg still have VMS but are not bothersome)
- Clinical hypnosis
 - Has been shown to reduce VMS frequency and severity

25

Treatment: vaginal dryness

- Vaginal estrogen
 - Cream dose: 0.5 g daily x 2 wk then twice weekly
 - Goal is to treat distal 1/3 of vagina
 - Increases vaginal wall thickness, decreases vaginal pH, improves vaginal dryness, dyspareunia, and sexual function

26

Treatment: vaginal dryness

- Vaginal hyaluronic acid
- Draws water into tissue
- Increases the thickness of the vaginal epithelium
- Vulvar moisturizer
 - Produces moist film over epithelium of vagina to lubricate vaginal walls
- Improves vaginal pH, dryness, dyspareunia, and sexual function

27

Treatment: vaginal dryness

- · CO2 and Erbium laser
 - Laser applied to vaginal epithelium so that fractional beams of light penetrate tissues creating small wounds in the epithelium. This leads to stimulation of collagen remodeling and regeneration
 - Improves subjective and objective atrophy, urinary symptoms, sexual function, dyspareunia, and dryness


28

Treatment: Genitourinary Syndrome of Menopause GSM

Ospemifene

 SERM which activates estrogen receptors in the vagina to increase wall thickness and reduce pain due to vulvar vaginal atrophy

- Topical DHEA
- Converts to estrogen in vulvar vaginal tissues
- Increases vaginal wall thickness, decreases vaginal pH, improves vaginal dryness, dyspareunia, and sexual function
- Vaginal testosterone
- Induces proliferation of vaginal epithelium
- Improves atrophy, dryness, and sexual function



Treatment - poor sleep

- Cognitive behavioral treatment insomnia
- Melatonin
- Gabapentin 100-300 mg at night

31

Case Discussion

 47 year old female patient presents with menstrual changes, hot flushes, night sweats, poor sleep, moodiness. Periods typically regular until a few years ago. Periods are now irregular and heavy in flow. She has family history of breast cancer and is worried about using hormones.

32

Case Discussion

- Evaluate AUB (TVUS, Embx)
- Treatment options
 - OCP
 - Levonorgestrel IUD + estrogen patch
 - Endometrial ablation or hysterectomy alone will not address all of her symptoms

33

References

- Santoro, Nanette MD. Perimenopause: From Research to Practice. J Womens Health. 2016 Apr 1; 25(4): 332-339
- Shufelt, Chrisandra MD, et al. The 2023 Non Hormone Therapy Position Statement of The North American Menopause Society. *Menopause*: 2023 Vol 30, No 6, pp. 573-590

34

References

- Casiano Evans, Elizabeth A MD; et al. Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics & Gynecology 142(3):p 555-570, September 2023. | DOI: 10.1097/AOG.00000000005288
- Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. ACOG Practice Bulletin Number 128 July 2012 (Reaffirmed 2024)

References

- Hormone Contraception and Risk of Breast Cancer. ACOG Practice Advisory January 2018
- Bromberger JT, et al. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). *Psychol Med* 2011; 41:1879-1888.